Oligomerix Awarded $0.5 M phase I NIH SBIR Fast-Track Grant to Conduct Safety Studies that will Support Clinical Studies of OLX-07010 for Alzheimer’s Patients
Home > News > Oligomerix Awarded $0.5 M phase I NIH SBIR Fast-Track Grant to Conduct Safety Studies that will Support Clinical Studies of OLX-07010 for Alzheimer’s Patients
Oligomerix > News > Oligomerix Awarded $0.5 M phase I NIH SBIR Fast-Track Grant to Conduct Safety Studies that will Support Clinical Studies of OLX-07010 for Alzheimer’s Patients
Oligomerix Awarded $0.5 M phase I NIH SBIR Fast-Track Grant to Conduct Safety Studies that will Support Clinical Studies of OLX-07010 for Alzheimer’s Patients
